Die FDA bietet keinen selbst aktualisierenden News-Dienst an, Informationen über aktuelle FDA-Zulassungen können auf der FDA-Homepage eingesehen werden.

Der kommerzielle Anbieter drugs.com publiziert einen Nachrichtendienst mit Informationen zu allen Neuzulassungen der FDA.

• Incyte Announces FDA Approval of Jakafi XR (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease
  01.05.2026
  WILMINGTON, Del.–(BUSINESS WIRE)–May 1, 2026– Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi XR™ (ruxolitinib) extended-release tablets for […]
• FDA Approves Veppanu (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer
  01.05.2026
  NEW HAVEN, Conn., May 01, 2026 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), today with its partner Pfizer Inc. (NYSE: PFE), announced that the U.S. […]
• ADMA Biologics Announces FDA Approval to Expand the Label for Asceniv to Include Pediatric Immune Compromised Patients Two Years of Age and Older
  30.04.2026
  RAMSEY, N.J. and BOCA RATON, Fla., May 04, 2026 (GLOBE NEWSWIRE) — ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end […]
• Axsome Therapeutics Announces FDA Approval of Auvelity (dextromethorphan HBr and bupropion HCl) for the Treatment of Agitation Associated with Dementia due to Alzheimer’s Disease
  30.04.2026
  NEW YORK, April 30, 2026 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central […]
• FDA Approves Langlara (insulin glargine-aldy), an Interchangeable Biosimilar to Lantus
  29.04.2026
  PHILADELPHIA – May 4, 2026 – Lannett Company, Inc., Lanexa Biologics, a wholly owned subsidiary of Lannett, and Sunshine Lake Pharma today announced that the […]